Who are lamivudine or entecavir's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lamivudine-or-entecavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

lamivudine or entecavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lamivudine or entecavir (lamivudine or entecavir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI). Area: Virology / Infectious Disease.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI) Hepatitis B virus reverse transcriptase; HIV reverse transcriptase Virology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

lamivudine or entecavir (lamivudine or entecavir) — Sun Yat-sen University. Lamivudine and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication by inhibiting the reverse transcriptase enzyme of hepatitis B virus (HBV) and HIV.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lamivudine or entecavir TARGET	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI) class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lamivudine or entecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/lamivudine-or-entecavir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab